Evidence map›Paper›PMID 34178213›Full record

ArticleThe Pan African medical journal2021

Comparison of Amplix® hepatitis B virus and Roche COBAS AmpliPrep/COBAS Taqman hepatitis B virus assay in quantifying HBV DNA in plasma of chronic hepatitis B in Senegal.

Gora Lô, Anna Julienne Selbé Ndiaye, Amina Sow, Amina Fall, Aissatou Sow, Oumar Barry, Ndèye Marième Diop, Halimatou Diop Ndiaye, Ndèye Coumba Touré Kâne, Souleymane Mboup

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Pan African medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gora LôCentre Médical Inter Armées Lemonier, Dakar, Sénégal.
Anna Julienne Selbé NdiayeInstitut de Recherche en Santé, de Surveillance Epidémiologique et de Formation, Dakar, Sénégal.
Amina SowInstitut de Recherche en Santé, de Surveillance Epidémiologique et de Formation, Dakar, Sénégal.
Amina FallCentre Médical Inter Armées Lemonier, Dakar, Sénégal.
Aissatou SowInstitut de Recherche en Santé, de Surveillance Epidémiologique et de Formation, Dakar, Sénégal.
Oumar BarryCentre Médical Inter Armées Lemonier, Dakar, Sénégal.
Ndèye Marième DiopCentre Médical Inter Armées Lemonier, Dakar, Sénégal.
Halimatou Diop NdiayeInstitut de Recherche en Santé, de Surveillance Epidémiologique et de Formation, Dakar, Sénégal.
Ndèye Coumba Touré KâneInstitut de Recherche en Santé, de Surveillance Epidémiologique et de Formation, Dakar, Sénégal.
Souleymane MboupInstitut de Recherche en Santé, de Surveillance Epidémiologique et de Formation, Dakar, Sénégal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionquantification of hepatitis B virus DNA, a key element in the management of chronic hepatitis B, allows a more direct and reliable measurement of viral replication and monitoring of the virological response to therapy. Polymerase chain reaction (PCR) platforms performing this quantification and adaptable to intermediate laboratories have been developed. Thus, this study was conducted to evaluate the on-site performance of the AMPLIX® hepatitis B virus (HBV) real-time PCR technique in comparison with the COBAS AmpliPrep™ technique.

methodsperformance of the AMPLIX® HBV real-time PCR technique was evaluated with repeatability and intermediate precision (reproducibility) determined. The comparison with COBAS Taqman was performed by testing, in parallel, 42 plasma samples. The statistical analysis using Meth Val® software was focused on correlation and concordance determination.

resultsAMPLIX® real-time PCR assay showed good reproducibility for the low (CV=6.65%) and high (CV=3.15%) control levels but also good repeatability for both the low (CV=2.12%) and high (CV=1.60%) concentration levels. Accuracy obtained in our study were less than acceptability limit fixed to 5%. Viral load measurements between Amplix and COBAS Taqman correlated strongly with a correlation coefficient of 0.97%. Concordance analysis gave an average of the differences of 0.54 log IU/L between the viral load measurements of the 2 techniques.

conclusionbased on these results, the Amplix real-time PCR platform for the quantification of HBV DNA can be considered as a reliable system for the monitoring of chronic hepatitis B and also a system adapted to intermediate laboratories.

Indexed as

DNA, ViralHepatitis B, ChronicHepatitis B virusHumansNucleic Acid Amplification TechniquesReal-Time Polymerase Chain ReactionReproducibility of ResultsSenegalViral LoadDNA, ViralAmplix®deoxyribonucleic acidhepatitis B virusRoche COBAS AmpliPrep/COBAS Taqman

Identifiers

PMID34178213
PMCPMC8197065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.